Caplin Point Laboratories, situated in Chennai, has outlined a 350 crore capital expenditure strategy to increase its current capacity, engage in greenfield projects to diversify its product line, and backward-integrate certain of its products.
D Muralidharan, CFO of Caplin Point Laboratories Ltd., stated during the company’s Q4FY23 earnings call that between now and H1FY25, “we will be expending 350 crore in capex for our ongoing projects and greenfield expansions.”
Caplin Point Laboratories was founded in 1990 and specialises in research and development (R&D), producing final formulations, and active pharmaceutical ingredients (API). The company produces both generic and branded versions of a variety of completed dosage forms, including tablets, capsules, injections, liquid orals, and ointments and creams.
While Caplin Point Laboratories caters predominantly to emerging markets of Latin America and Africa, its wholly-owned subsidiary Caplin Steriles Ltd., caters to regulated markets, such as the US and Europe, for injectable and ophthalmic products.
